TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer

Future Oncology

Volumn 7, Issue 4, 2011, Pages 497-506

  Oudard, Stephane ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

cabazitaxel; docetaxel; metastatic castration resistant prostate cancer

Indexed keywords

CABAZITAXEL; DOCETAXEL; MITOXANTRONE; PREDNISONE; TAXANE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CAUSE OF DEATH; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASTRATION; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; HUMANS; MALE; MITOXANTRONE; NEOPLASM METASTASIS; PREDNISONE; PROSTATIC NEOPLASMS; TAXOIDS; TUBULIN;

EID: 79953722553     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.23     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765-781 (2010).
3. Horwich A, Parker C, Kataja V: Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 76-78 (2009).
4. Tannock IF, De Wit R, Berry WR et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Eng. J. Med. 351(15), 1502-1512 (2004). (Pubitemid 39315317)
5. Berthold D R, Pond GR, Soban F, De Wit R, Eisenberger M, Tannock IF: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26(2), 242-2 45 (2008).
6. Petrylak DP, Tangen CM, Hussain MH et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004). (Pubitemid 39315318)
7. Oudard S, Banu E, Medioni J et al.: What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int. 103(12), 164 1-1646 (2009).
8. Oudard S, Banu E, Scotte F et al.: Prostate-specifc antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann. Oncol. 18(11), 1828-1833 (2007). (Pubitemid 350111569)
9. Sternberg CN, Petrylak DP, Sartor O et al.: Multinational, double-blind, Phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate ca ncer progressing after prior chemotherapy: the SPARC trial. J. Clin. Oncol. 27(32), 5431-5438 (2009).
10. de Bono JS, Oudard S, Ozguroglu M et al.: Prednisone plus cabazitaxel or mitoxantrone for metastat ic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147-1154 (2010).
11. Oberlies NH, Kroll DJ: Camptothecin and taxol: historic achievements in natural products research. J. Nat. Prod. 67(2), 129-135 (2004). (Pubitemid 38282896)
12. Attard G, Greystoke A, Kaye S, de Bono J: Update on tubulin-binding agents. Pathol. Biol. (Paris) 54(2), 72-84 (2006).
13. Engels FK, Sparreboom A, Mathot RA, Verweij J: Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br. J. Cancer 93(2), 173-177 (2005). (Pubitemid 41133202)
14. Bissery C, Bouchard H, Riou JF et al.: Preclinical evaluation of TXD258, a new taxoid. Proc Am. Assoc Cancer Res. 41, 214 (2000).
15. Dykes DJ, Sarsat JP, Bissery MC: Effcacy evaluati on of TXD258, a taxoid compound against orthotopic and subcutaneous glioblastomas. Presented at: 91st American Association for Cancer Research. San Francisco, CA, USA, 1-5 April 2000.
16. Vrignaud P, Lejeune P, Chaplin D, Lavelle F, Bissery MC: In vivo effcacy of TXD258, a new taxoid, against human tumor xenografts. Presented at: 91st American Association for Cancer Research. San Francisco, CA, USA, 1-5 April 2000.
17. Cisternino S, Bour asset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM: Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br. J. Pharmacol. 138(7), 1367-1375 (2003). (Pubitemid 36543135)
18. Mita AC, Denis LJ, Rowinsky EK et al.: Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with adva nced solid tumors. Clin. Cancer Res. 15(2), 723-730 (2009).
19. Pivot X, Koralewski P, Hidalgo JL et al.: A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxan e-resistant metastatic breast cancer patients. Ann. Oncol. 19(9), 1547-1552 (2008).
20. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L: Phase III study of mitoxantrone plus low dose prednisone ver sus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J. Urol. 168(6), 2439-2443 (2002). (Pubitemid 35402635)
21. Osoba D, Tannock IF, Ernst DS, Neville AJ: Health-related qualit y of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J. Clin. Oncol. 17(6), 1654-1663 (1999). (Pubitemid 29269233)
22. Oudard SM, de Bono JS, Ozguroglu M et al.: Cabaz itaxel plus prednisone/prednisolone signifcantly increases overall survival compared to mitoxantrone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: fnal results wit h updated overall survival of a multinational Phase III trial (TROPIC). Ann. Oncol. 21(Suppl. 8), VIII271 (2010).
23. Smith TJ, Khatcheressian J, Lyman GH et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24(19), 3187-3205 (2006). (Pubitemid 46638957)
24. de Bono JS, Logothetis C, Fizazi K et al.: Abiraterone acetate plus low dose p rednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled Phase 3 study. Ann. Onc ol. 21(Suppl. 8), VIII3 (2010).
25. Donovan D, Vahdat LT: Epothilones: clinical update and future directions. Oncology (Williston Park). 22(4), 408-416 (2008).
26. Harzstark AL, Rosenberg JE, Weinberg VK et al.: Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a Phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer DOI: 10.1002/cncr.25810 (2010) (Epub ahead of print).
27. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR: Phase II trial of weekly patupilone in patients with cas tration-resistant prostate cancer. Ann. Oncol. 20(3), 492-497 (2009).